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NAADP-Dependent Ca2+ Signaling 
Controls Melanoma Progression, 
Metastatic Dissemination and 
Neoangiogenesis
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Elio Ziparo1, Fioretta Palombi1 & Antonio Filippini1
A novel transduction pathway for the powerful angiogenic factor VEGF has been recently shown in 
endothelial cells to operate through NAADP-controlled intracellular release of Ca2+. In the present 
report the possible involvement of NAADP-controlled Ca2+ signaling in tumor vascularization, growth 
and metastatic dissemination was investigated in a murine model of VEGF-secreting melanoma. Mice 
implanted with B16 melanoma cells were treated with NAADP inhibitor Ned-19 every second day for 
4 weeks and tumor growth, vascularization and metastatization were evaluated. Control specimens 
developed well vascularized tumors and lung metastases, whereas in Ned-19-treated mice tumor 
growth and vascularization as well as lung metastases were strongly inhibited. In vitro experiments 
showed that Ned-19 treatment controls the growth of B16 cells in vitro, their migratory ability, 
adhesive properties and VEGFR2 expression, indicating NAADP involvement in intercellular autocrine 
signaling. To this regard, Ca2+ imaging experiments showed that the response of B16 cells to VEGF 
stimulation is NAADP-dependent. The whole of these observations indicate that NAADP-controlled 
Ca2+ signaling can be relevant not only for neoangiogenesis but also for direct control of tumor cells.
Vascular endothelial growth factor (VEGF) and its receptor VEGFR2 play a pivotal role in stimulating angiogen-
esis, including vascularization of solid tumors1. Angiogenesis is an important step in the outgrowth of tumors2 
controlling their dissemination, progression and metastasis. Therapeutic targeting of angiogenesis is therefore an 
important challenge, still in need of basic research. In particular, no clinical tool is at present successful in inhibit-
ing the long-term response to VEGF, the most important angiogenic factor overexpressed by the vast majority of 
human cancers3. Owing to the central role of VEGF, the first angiogenic inhibitors designed for clinical use were 
targeted against VEGF and its tyrosine kinase receptor4. VEGF neutralizing antibodies and some multi-target 
tyrosine kinase inhibitors have been approved for clinical use, and many more are being evaluated in clinical tri-
als5. Although these therapies provide improvement in progression-free or overall survival, they are nonetheless 
met with drug tolerance and side effects, attesting to the complexity of VEGF signaling and tumor angiogenic 
cascade. Anti-VEGF treatments can induce adverse effects, possibly due to the blockade of the entire complex of 
VEGF signaling pathways resulting in ‘off-target’ effects6–9. These findings suggest that the challenge represented 
by therapeutic targeting of angiogenesis in advanced cancer is an interesting aim to further pursue through better 
characterization of the intracellular pathways involved in the response to VEGF.
Melanoma is one of the most aggressive and highly metastatic cancers. It is known that VEGF levels are asso-
ciated with melanoma progression10,11 and are used as prognostic indicators12, but the molecular mechanisms 
regulating the interaction between tumor and endothelial cells (ECs) and their role in cancer cell extravasation and 
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metastasis are still unclear. Several studies have shown the vascular system to be pivotal for metastasis in melanoma. 
Consequently, the effect of different antiangiogenic therapies has been and is being investigated in preclinical and 
clinical trials focusing on inhibition of either VEGF signaling or different angiogenic factors13. However, overall 
survival rates have not significantly improved in clinical trials with antiangiogenic agents due to the resistance to 
anti-VEGF therapy. Therefore the therapy of malignant melanoma remains challenging.
Both tumor growth and metastatic spreading depend on the formation of new blood vessels, to promote which 
tumor cells secrete angiogenic growth factors that act on the neighbouring ECs, inducing proliferation and migra-
tion. These processes are highly controlled by the ubiquitous second messenger Ca2+, recognized as a relevant 
factor in the growth of tumors and metastatic behaviour of cancer cells and focus of a novel area of research in 
oncology14,15. Cancer cells present alterations in Ca2+ fluxes across the plasma membrane that reflect changes in 
the expression, localization and/or function of different types of Ca2+ channels. In particular, the expression of 
different members of the transient receptor potential (TRP) family has been shown to be altered in cancer cells. 
In melanoma different transient receptor potential melastatins (TRPM) are expressed; several studies point to 
TRPM1 as responsible for tumor suppression, and both metastatic progression and aggressiveness of melanoma 
are correlated to the loss of TRPM1 expression16,17. Moreover, in many tumors other than melanoma, depletion 
of Ca2+ from the ER may drive tumor growth by inducing Ca2+ influx through the plasma membrane, mediated 
by the store operated calcium entry (SOCE) canonical components. Endoplasmic Ca2+ depletion sensor (STIM1) 
translocates to the plasma membrane and activates Ca2+ influx channel (ORAI1). These channels are highly 
expressed in human melanoma and in melanoma cell lines18. Voltage gated calcium channels (VGCCs) are also 
involved in melanoma progression by generating oscillatory Ca2+ waves that favour cell cycle progression19. These 
data show that regulation of intracellular Ca2+ has an important impact on melanoma growth and metastasis, 
but little is known about the involvement of intracellular calcium ([Ca2+]i) release in melanoma. It is known that 
calcium release from endoplasmic reticulum (ER) via PLC/IP3 pathway is involved in melanoma cell migration, 
invasion and metastasis20,21. In addition, Vartarian et al. highlighted the importance of both extracellular and 
intracellular Ca2+ concentration in integrin distribution and cytoskeleton remodelling in melanoma22. Increases 
in [Ca2+]i are regulated by different Ca2+-mobilizing messengers: besides IP3 and cyclic adenosine diphosphor-
ibose (cADPR), which mobilize Ca2+ from ER stores, nicotinic acid adenine dinucleotide phosphate (NAADP) 
has been more recently identified as capable of triggering Ca2+ release from acidic organelles, such as lysosomes 
and endosomes23,24 and appears to be a pivotal trigger for many Ca2+ signaling events25. NAADP likely targets 
two-pore channels (TPCs)26,27 which are distinct from IP3 receptors (IP3Rs) and ryanodine receptors (RyRs), and 
the resulting localized NAADP-evoked Ca2+ signals may in some cases be globalized via IP3Rs and RyRs through 
Ca2+-induced Ca2+ release28–30. A powerful tool in NAADP signaling characterization is represented by the selective 
membrane-permeant non competitive antagonist Ned-19, which blocks NAADP-mediated Ca2+ signaling31–33.
We have recently demonstrated in ECs the direct relationship between NAADP-mediated Ca2+ release and the 
specific signaling mechanism controlling angiogenesis33: the detection of a master NAADP/TPC2/Ca2+ machin-
ery controlling VEGF-induced angiogenesis could contribute to the identification of new targets for therapeutic 
strategies. On this basis, and given the paracrine dialogue between endothelium and tumor, we have investigated 
the direct and indirect involvement of NAADP-mediated Ca2+ signaling on melanoma proliferation, invasivity 
and angiogenesis. Our results indicate that specific targeting of NAADP –dependent Ca2+ release in vitro and 
in vivo results in the twofold benefit of exerting both antitumor and antiangiogenic effects.
Results
In vivo toxicology and pharmacokinetic parameters of Ned-19. In order to test the safety of Ned-19 
treatment in vivo, we performed toxicological studies on adult male C57BL/6 mice intraperitoneally injected with 
different concentrations (5, 20 mg/Kg) of Ned-19. Diastolic pressure, pulse rate and weight were monitored once 
a week. When intraperitoneally injected in mice over a period of 4 weeks, 5 mg/Kg Ned-19 did not substantially 
affect either pulse rate or weight, while diastolic pressure, though variable, remained within physiological values 
(Fig. 1a–c). Moreover, this schedule of Ned-19 administration did not produce any adverse effects as monitored 
by postural and behavioral changes. The in vivo biopharmaceutical profile of Ned-19 was studied by measuring 
pharmacokinetic parameters in plasma samples, obtained at fixed times after one intraperitoneal (i.p) injection 
of 5 mg/Kg Ned-19. Results showed that Ned-19 was very rapidly absorbed reaching maximum plasma concen-
trations 30 min after injection (Fig. 1d).
Ned-19-mediated inhibition of tumor growth and vascularization. On the basis of the safety and 
pharmacokinetic parameters reported above, every second day administration of 5 mg/Kg Ned-19 was chosen to 
investigate the effect of this inhibitor on tumor growth and angiogenesis in mice inoculated with B16 cells. Our 
results show that, in comparison to vehicle-treated specimens, tumor growth was severely impaired by 4-week i.p. 
Ned-19 administration (Fig. 2a,b) in the absence of adverse health effects, suggesting the involvement of NAADP 
signaling in this tumor. In fact, the comparative histological analysis of tumors from treated and untreated mice 
showed that the density of CD31 positive tumor vessels was reduced by Ned-19 treatment (Fig. 2c). An addi-
tional tumor feature affected by Ned-19 was its metastatic behaviour. Since melanoma B16 is known to induce 
the formation of spontaneous metastasis in lungs, fixed lungs of Ned-19-treated and untreated mice were mac-
roscopically and microscopically inspected for the presence of metastatic nodules. Ned-19 was found to drasti-
cally reduce the formation of total lung metastases (micro and macro- metastases) (Fig. 2d), possibly suggesting 
impaired melanoma cell entry into the blood flow following Ned-19-induced reduction of primary tumor vas-
cularization. The hypothesis of a possible contribution from a direct response of melanoma cells to Ned-19 is 
addressed in the experiments described below.
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Evaluation of VEGF-induced Ca2+ release in melanoma B16 cells. VEGF is produced by a large 
variety of tumors, including melanoma34,35, in which it appears to play an important role in the process of 
tumor-induced angiogenesis3. Several studies in the literature have focused on the presence in melanoma cells, 
but not in melanocytes, of the VEGF receptors VEGFR236,37 and, more recently, VEGFR138.
It is known that in melanoma cell lines several biological processes are controlled by [Ca2+]i 20,21. To charac-
terize the possible contribution of VEGF to Ca2+ signaling, B16 cells were stimulated with VEGFA165 (known as 
VEGF) and [Ca2+]i was assayed in FURA-2AM loaded single cells. Figure 3a,b show that VEGF stimulation trig-
gers Ca2+ signaling in B16 melanoma cells. In order to evaluate the possible involvement of NAADP-dependent 
intracellular compartments in VEGF-induced Ca2+ mobilization we adopted a pharmacological approach using 
thapsigargin, which blocks ER SERCA pumps and bafilomycin A1, which inhibits pH-dependent Ca2+ uptake 
into acidic stores by inhibition of the vacuolar-type H+-ATPase pump23. VEGF-induced Ca2+ release was signif-
icantly impaired not only by thapsigargin (Fig. 3c,d), but even more by bafilomycin A1 (Fig. 3e,f), showing the 
involvement of acidic Ca2+ stores in the response to VEGF. The role of NAADP indicated by these experiments was 
then confirmed by the observation that pretreatment of B16 cells for 30 min with 25, 50 and 100 μ mol/L Ned-19 
Figure 1. Vital parameters and analysis of Ned-19 pharmacokinetics in C57BL/6 mice. (a–c) Measuments of 
mice weight, pulse rate and diastolic pressure after i.p. injection of 5 mg/Kg Ned-19 every 48 h over four weeks. 
Each point is the mean of five independent measurements ± s.e.m. (d) Time course of Ned-19 concentrations in 
mouse plasma following i.p. administration (5 mg/Kg Ned-19). Each point is the mean of four replicates ± s.e.m. 
*P < 0.05; **P <  0.01; ***P < 0.0001.
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concentration-dependently inhibits VEGF-induced Ca2+ release (Fig. 3g,h). These experiments show for the first 
time that NAADP controls VEGF-evoked Ca2+ signaling in B16 cells.
B16 cell migration is modulated by NAADP-dependent Ca2+ release. Tumor growth and meta-
static spreading depend on the formation of new blood vessels, which tumor cells stimulate by paracrine secre-
tion of angiogenic growth factors. Both proliferative and migratory behaviour of melanoma cells are known 
to be highly controlled by the ubiquitous second messenger Ca2+. Given the observed role of NAADP in the 
response of B16 cells to VEGF in vitro, we investigated whether also the proliferative and migratory ability of 
these cells is controlled by this second messenger. Boyden chamber migration assays (Fig. 4a) clearly showed that 
melanoma cell migration is reduced by Ned-19 treatment. Cell migration and invasion of extracellular matrix 
involve reorganization of the actin cytoskeleton. We observed that Ned-19 significantly reduced the activation 
of the focal adhesion kinase (FAK) known to play a key role in regulating the dynamic changes in actin cytoskel-
eton reorganization (Fig. 4b1). In melanoma progression, metastasis is accompanied by down-regulation of 
E-cadherin and up-regulation of N-cadherin expression, which facilitate the separation of melanoma cells from 
adjacent E-cadherin-expressing keratinocytes and the invasion of the dermal tissue through interactions with the 
N-cadherin-expressing fibroblasts39. Treatment of melanoma cells with Ned-19 resulted in reduced expression of 
N-cadherin and increased expression of E-cadherin, affecting the cell migratory behaviour (Fig. 4b2). This was 
paralleled by cell shape changes apparent in phase contrast microscopy during 24, 48 and 72 h Ned-19 treatment 
Figure 2. Ned-19 inhibits the growth, vascularization and metastatic potential of B16 tumors. (a,b) B16 
cells were subcutaneously inoculated in C57BL/6 mice and treated as indicated in Material and Methods. 
Analysis of tumour size increase (mm3) in mice injected i.p. with Ned-19 or DMSO (vehicle). (a) Graph of 
a representative experiment (mean ± s.e.m). Each group consists of minimum 6 mice. Comparable results 
were obtained in three independent experiments. (b) Representative pictures of tumours from mice treated 
as indicated. (c) Tumor vascularization in samples treated or not with Ned-19 for four weeks. ECs were 
recognized as CD31+. (c1) Vessel density. (c2) Representative histological sections of tumors immunostained 
for CD31 (red). (d) Lung metastastes from mice treated or not with Ned-19 for four weeks. (d1) Number of total 
metastases. (d2) Representative H&E stained histological sections in which metastases are indicated by arrow 
heads. Where applicable, values are expressed as mean ± s.e.m. from three independent experiments. *P < 0.05.
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(Fig. 4c). NAADP-mediated Ca2+ release is thus required for the migratory ability of B16 cells in their own con-
ditioned medium.
Ned-19 inhibits B16 melanoma cell viability, proliferation and VEGFR2 expression. The involve-
ment of NAADP in B16 cell proliferation was evaluated using the NAADP antagonist Ned-19 and measuring 
different indicators. The number of viable cells, assessed by the thiazolyl blue tetrazolium bromide (MTT) assay 
for spectrophotometric determination of cell viability, was reduced from 24 h up to 72 h following Ned-19 treat-
ment (Fig. 5a). Flow cytometry assessment showed that the cell number was markedly reduced by Ned-19 while 
control cells, either untreated or vehicle-treated, underwent exponential growth (Fig. 5b). The reduction in cell 
number resulting from Ned-19 treatment was consistent with the reduction of the S phase percentage and the 
increase of the G0/G1 phase percentage evaluated by cell cycle analysis (Fig. 5c,d). These results suggest that 
melanoma B16 cell proliferation is dependent upon NAADP-mediated Ca2+ release, showing that Ned-19 treated 
cells are arrested in S phase and undergo an increase in % subG1 population after 72 h (Fig. 5e). To get insight on 
the composition of the subG1 population, samples were further analysed in flow cytometry by annexin V-FITC 
(Fig. 5f1,f2) and propidium iodide (PI) (Fig. 5g) staining, demonstrating that the percentage of apoptotic cells, 
which was highest at 72 h, was less than 15%.
Having observed the effect of NAADP inhibition on B16 cell proliferation and migration we wondered whether 
VEGFR2 expression was also affected by this inhibitor. As shown in Fig. 5h Ned-19 treatment down-regulates 
VEGFR2 expression starting from 24 h suggesting a further mechanism through which NAADP inhibition exerts 
its antitumor effects.
Discussion
VEGF/VEGFR2 complex represents a promising target for therapeutic strategies aimed at inhibiting neoangi-
ogenesis. We have recently identified a novel VEGFR2-specific signaling pathway that crucially controls in vivo 
neoangiogenesis through NAADP-operated release of Ca2+ from intracellular acidic stores33. This previous finding 
prompted us to investigate whether endogenously-induced angiogenesis taking place in a solid tumor could be 
similarly impaired by pharmacological inhibition of NAADP signal. The evidence we obtained and report here 
goes beyond expectation, showing that in a murine model of highly aggressive and highly metastatic tumor, known 
to secrete VEGF35,40, Ned-19 inhibits neoangiogenesis, formation of metastases and tumor growth, unexpectedly 
exerting its action also on tumor cells. The conditions in which angiogenesis occurs in a normal tissue site following 
Figure 3. VEGF mobilizes calcium activating Ca2+ release from acidic stores. Live imaging in single FURA-
2AM loaded cells; representative traces and maximum Ca2+ concentrations, shown as bar charts. Intracellular 
Ca2+ levels in B16 cells after stimulation with 100 μ g/L VEGF: (a) bar charts, (b) representative traces.  
(c–f) Identification of VEGF activated intracellular Ca2+ stores. Ca2+ release in cells stimulated with 100 μ g/L 
VEGF after treatment with either vehicle alone (control) or (c,d) 1 μ mol/L thapsigargin for 15 min or  
(e,f) 0.5 μ mol/L bafilomycin A1 for 1 h. (g,h) Cells were pretreated with 25, 50 or 100 μ mol/L Ned-19 for 
30 min, then stimulated with 100 μ g/L VEGF. Arrow indicates time of agonist addition. Each data point in 
bar charts represents mean ± s.e.m. from three to five independent experiments, n = 35–139 cells. **P < 0.01; 
***P < 0.0001.
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administration of a single growth factor differ in many ways from those in which it takes place, spontaneously, in 
the context of a solid tumor. First of all a variety of cell types are present at the tumor site, contributing to the local 
microenvironment41. The specific and complex interplay of local signals characterizing tumor microenvironment 
is known to originate from a number of variables such as the heterogeneity of tumor cell population and the extent 
of stromal cell involvement42,43. Moreover, differences between normal and tumor vessels, not only in morphology 
and in functionality but also in origin and mode of formation are well known44–46. As a consequence of this dynamic 
complexity the specific microenvironment in which a pharmacological inhibitor is tested is far from defined, and 
the cascade of events linking the intended initial target to the final outcome is not easily identified. The experiments 
performed on melanoma cell cultures were in fact aimed at providing some clues in this direction and the data 
obtained have allowed for some deductions on the in vivo counterpart. Below, data from the two experimental 
approaches are analyzed and discussed in parallel.
Pharmacological treatment with NAADP inhibitor is usually performed in vitro. To our knowledge, in vivo 
use of Ned-19 has been reported so far only from our laboratory33 as a component of Matrigel plugs implanted in 
mice for angiogenesis experiments. In the present research, the systemic effects of repeated i.p. administration of 
Ned-19 were preliminary tested on weight, diastolic pressure, and pulse rate. These parameters were chosen as it has 
been shown47 that rats administered with NAADP-AM (the cell permeant NAADP derivative) undergo decrease 
in arterial pressure. In our experiments, the first to our knowledge testing the drug in animals, Ned-19 did not 
substantially affect either pulse rate or weight, while diastolic pressure remained within physiological values; in 
Figure 4. Ned-19 inhibits B16 cell migration and adhesivity. (a) Cells treated as indicated were allowed 
to migrate for 24 h across the membrane in Boyden chambers. (a1) Cells that migrated into the filter were 
Hoechst stained (a2) and counted in 20 fields per well. Results are expressed as migrating cells vs non-treated 
control (NT). (b1,b2) Cell lysates tested by Western blotting with a p-FAK specific antibody, anti E-cadherin, 
anti N-cadherin. β -actin was used as loading control. (c) Phase contrast images of B16 cells coltured in the 
indicated conditions. Data shown in (b,c) and their respective densitometric values are representative of 
three independent experiments. Where applicable, values are expressed as mean ± s.e.m. from three to five 
independent experiments. *P < 0.05; **P < 0.01.
www.nature.com/scientificreports/
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Figure 5. Ned-19 affects B16 cells proliferation rate, cell viability and VEGFR2 expression. Cells were 
treated with Ned-19 or vehicle (DMSO) as indicated for 24, 48, 72 h. (a) Cell viability quantified as OD (570 nm) 
by MTT assay. (b) Number of cells evaluated by flow cytometry. (c–e) Evaluation of % S phase, % G0/G1 phase, 
% subG1 population by cell cycle analysis. (f1) The percentage of annexin V- FITC positive cells studied by 
flow cytometry is shown in the histogram. (f2) Annexin V-FITC/ PI representative dot plot of cells treated for 
72 h with Ned-19; lower right quadrant: apoptotic cells; upper right and left quadrants: necrotic cells; lower left 
quadrant: live cells (for quadrants setting details see Methods section). (g) The percentage of live and dead cells 
in stimulated and control conditions was tested by flow cytometry using PI. (h) Cell lysates tested by Western 
blotting with a VEGFR2 specific antibody. β -actin was used as loading control. Data shown in (h) and their 
respective densitometric values are representative of three independent experiments. Values are expressed as 
mean ± s.e.m. from three to five independent experiments. *P < 0.05; **P < 0.01; ***P < 0.0001.
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fact, after a minor 24 h raise, it appeared stabilized within 48 h after treatment. Considering these parameters and 
pharmacokinetic data, every second day administration of 5 mg/Kg was chosen as a safe protocol to investigate 
the effect of Ned-19 on angiogenesis and tumor growth in mice inoculated with B16 cells.
The antitumor effect of NAADP inhibition on B16-derived tumors was apparent and manifold. I.p. Ned-19 
administration in B16 tumors bearing mice significantly impaired tumor growth compared to vehicle treated 
specimens. Moreover, the density of CD31 positive tumor vessels as well as the total number of lung metastases 
were strongly reduced by Ned-19 treatment.
More than one scenario could be envisaged when attempting to interpret these data. In the most reductive one, 
a linear chain might link all of the effects: Ned-19 would abolish the angiogenic response of ECs to locally produced 
VEGF48,49, in line with what known to occur in HUVEC33. Impaired development of vascularization would then 
result in poor support of tumor growth and inhibition of metastatic dissemination. A more likely hypothesis envis-
ages further contributions to this basic cascade converging to the same end point through a more complex interplay.
The possibility that tumor cells themselves could be sensitive to the inhibitor was taken into consideration in cell 
culture experiments. Treatment of B16 cells with Ned-19 was found to reduce the cell migratory ability paralleled 
by reduction in FAK activation, down-regulation of N-cadherin and up-regulation of E-cadherin expression. In 
accordance with this data it is known that intra-and extravasation of tumor cells, fundamental for metastatic inva-
sion, involve the expression of adhesion molecules such as cadherins and FAK, mediating the contact with endothe-
lial and subendothelial surfaces50. In the development of cutaneous melanoma, decreased expression of E-cadherin 
and increased expression of N-cadherin accompany cell detachment and transendothelial migration51 which is a 
critical process in cancer development and metastasis. Moreover, Ned-19 was found to reduce cell proliferation and 
time-dependently induce cell apoptosis. Interestingly, we observed that NAADP-inhibition induced a remarkable 
down regulation of VEGFR2 expression in B16 melanoma cells. The whole of these findings strongly indicate 
that these tumor cells are sensitive to the inhibition of NAADP-mediated Ca2+ signaling. A NAADP-operated 
system seems in fact to be active in the tumor cells themselves, controlling functions as relevant as proliferation, 
VEGFR2 expression and migratory abililty. Experiments of calcium imaging showed that in response to 100 μg/L 
VEGF, B16 cells undergo an [Ca2+]i release which is controlled by NAADP dependent acidic stores. The observed 
inhibitory effects of Ned-19 in unstimulated B16 cultures is therefore likely to indicate that these cells respond to 
autocrinally secreted VEGF by means of a NAADP-controlled Ca2+ signaling pathway. In consideration of the well 
known presence of VEGF in melanoma microenvironment35 it seems possible that this signaling pathway is active 
also in vivo, hence to hypothesise that it has contributed to the overall inhibitory effect of Ned-19 treatment in our 
in vivo model. The observed direct effect of Ned-19 on tumor cell viability and growth most likely entails altered 
production of tumor-derived proangiogenic factors. In as far as is legitimate to transfer in vitro evidence to in vivo 
models, the impaired vascularization of tumors in Ned-19 treated mice would then result not only from direct 
inhibition of EC response to VEGF33 but also from reduced supply of angiogenic factors. This framework is no 
doubt compatible with the possibility that in vivo Ned-19 may have affected additional targets, possibly interfering 
at multiple levels with the complex intercellular crosstalk specific of the tumor microenvironment.
Whatever the detailed roles of further possible players, the detection of a new level of vulnerability in the 
aggressive behaviour of melanoma represents a step forward towards the identification of potential therapeutic 
targets. Moreover, to our knowledge this is the first report on NAADP system involvement in tumor cells, a finding 
of broader potential interest, given the possibility that this Ca2+-mobilizing second messenger might play a crucial 
role in the biology of additional types of tumor cells.
Material and Methods
Chemicals and reagents. The following antibodies were used: Rabbit anti-phospho-FAK (Tyr925, Cell 
Signaling Technologies, Danvers, MA, USA), purified Mouse anti-N-cadherin (BD Biosciences, New Jersey, 
USA), Mouse anti-E-cadherin (Invitrogen, Life Technologies, Monza, Italy), Mouse anti-VEGFR2 (R&D, 
Minneapolis, MN), β -Actin HRP-conjugated (Sigma, Milano, Italy), stabilized Goat anti-Mouse HRP-conjugated 
(Thermo Fisher Scientific, Waltham, MA), stabilized peroxidase conjugated Goat anti-Rabbit [(H + L), Thermo 
Fisher Scientific]. Reagents used are: VEGF-A165 (Peprotech, Rocky Hill, NJ, USA), trans-Ned-19 (Tocris 
Bioscences, Bristol, United Kingdom), Bafilomycin A1 (Sigma), Thapsigargin (Sigma). Ned-19 was purchased 
from Tocris Bioscience and was at least 98% pure. Methanol and other organic solvents were chromatography 
grade from Sigma, water was purified using a milliQ system from Millipore (Billerica, MA, USA) and LC-MS 
grade formic acid was obtained from Fluka (Sigma). Centrifugal ultrafiltration devices were Amicon Ultra-0.5 
(Ultracel-3 K, regenerated cellulose 3,000 MW) from Millipore Co. Ltd.
Pharmacokinetic analysis. Mice were administered a single i.p. dose of 5 mg/Kg Ned-19. At times from 
0 min to 24 h after administration individual mice were sacrificed, blood samples were taken by cardiac punc-
ture, centrifuged at 250 g for 10 min at 4 °C and the resulting plasma were stored at − 80 °C until analyzed. 75 μ L 
mouse plasma was mixed with 75 μ L methanol. The mixture was vortexed for 1 min and applied to a 500 μ L 
centrifugal filter. The capped tube was then centrifuged at 12,000 g for 15 min at 25 °C. Eight microliter of the 
ultrafiltrate solution was directly injected into the HPLC system and Ned-19 analysis was performed as follow 
by liquid chromatography tandem mass spectrometry (LC-MS/MS). The HPLC equipment consists of a Series 
200 Micro-LC Pump and a Series 200 autosampler from Perkin Elmer (Norwalk, CT, USA). A triple quadrupole 
mass spectrometer, AB-Sciex API 2,000 (Toronto, ON, Canada) was used for detection. The analyte was analysed 
using a C18 phase Kinetex column (10 cm × 2.1 mm ID) from Phenomenex (Torrance, CA, USA) packed with 
2.6 μ m core–shell particles. A Phenomenex security GuardUltra Cartridge was also used to protect the column 
from damaging contaminants and microparticulates. The mobile phases were (A) methanol and (B) water, both 
containing 5% formic acid, at a flow rate of 0.4 mL/min and were entirely transferred into the mass spectrometer 
source. The gradient elution was as follows: increase of the organic phase from 0 to 5% in 1 min, then to 30% in 
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the following minute and linearly to 100% in 0.5 min. Finally, after 1 min of 100% methanol the organic phase 
was reduced to the original 0% in 2.5 min to enable equilibration of the column. The resulting total run time was 
6 min. Ned-19 was detected in positive ionization with a capillary voltage of 5,500 V, nebulizer gas (air) at 45 psi, 
turbo gas (nitrogen) at 80 psi and 425 °C. The other ion source parameters were set as follows: curtain gas (CUR), 
25 psi; collision gas (CAD), 5 psi; declustering potential (DP), 60 V; entrance potential (EP), 12 V. Instrument 
conditions optimization was performed by direct infusion and manual tuning. A 100 ng/mL methanolic solu-
tion was prepared for this purpose. Data collection and elaboration were performed by means of Analyst 1.4 
software (AB- Sciex). The quantitative data were acquired using Multi Reaction Monitoring (MRM) mode. Two 
MRM transitions (precursor ion > fragment ion) were selected for the analyte, namely m/z 515.2 > 442.1 and 
515.2 > 262.2. Collision energy (CE) was set at 23 and 38 eV while collision cell exit potential (CXP) was at 22 and 
13 V for the two transitions respectively.
Ned-19 stock solutions were prepared by dissolving analyte in the appropriate amount of methanol in order 
to obtain individual stock solutions at 1,000 μ g/mL. The stock solution was further diluted to obtain standard 
stock solutions containing 100 and 1 μ g/mL analyte. All the stock solutions were stored at − 20 °C. The analytical 
method was validated according to FDA guidelines for bioanalytical method validation. Linearity, recovery, matrix 
effect, precision, accuracy, limits of detection (LODs) and lower limits of quantification (LLOQs) were evaluated. 
Calibration standard solutions were prepared in water: methanol (50/50, v/v) by dilution of the appropriate stock 
solution; the calibration range was 1 to 500 ng/mL; the calibrators were prepared at 7 concentrations. Precision, 
recovery and accuracy were evaluated at 3 concentrations (1, 75, 500 ng/mL) and the resulting values were found 
to fall within acceptable limits. The extraction recovery for Ned-19 was 69 ± 6%. Matrix effect was not significant 
over the linearity range (< 10%). The limit of detection (LOD) was defined as the lowest concentration with a 
signal-to-noise (S/N) ratio greater than 3. The limit of quantification (LOQ) was defined as the concentration at 
which both precision (RSD %) and accuracy were less than 20%. To this purpose mouse plasma spiked with the 
analyte and subjected to the extraction step at concentrations ranging from 0.2 to 2 ng/mL were analysed in trip-
licate. LLOQ was found to be 0.5 ng/mL while LOD was 0.2 ng/mL.The validated method was then successfully 
applied in measuring Ned-19 following drug injection in mice to support the pharmacokinetic study.
B16 melanoma cell line culture. B16 murine melanoma cell line provided by Dr. L. Morasca (Mario 
Negri Institute, Milan, Italy) was maintained in Dulbecco’s modified Eagle’s medium (Sigma) supplemented with 
2 mmol/L glutamine (Sigma), 10% fetal calf serum (Sigma), and antibiotics (P/S, Sigma).
B16 tumor cells transplant in syngenic mice. Six to ten-week-old male C57BL/6 mice were purchased 
from Charles River Laboratories (Calco, LC,Italy). The animals were housed at the University of Rome Histology 
Unit accredited animal facility, in individual cages in an environmentally controlled room (23 °C, 12 h light–dark 
cycle) and provided with food and water ad libitum. All of the procedures were approved by the Italian Ministry 
for Health and conducted according to the US National Institutes of Health guidelines. 4 × 106 B16 cells were 
resuspended in 200 μ l PBS. The cells suspension was subcutaneously injected into the flank of the mice. Tumors 
were grown to ≈ 50–100 mm3 before starting treatment with Ned-19 or vehicle (DMSO). I.p. injection of 5 mg/Kg 
Ned-19 was performed every 2 days for 4 weeks. Tumor volume based on caliper measurements was calculated by 
the modified ellipsoidal formula (tumor volume = ½ × (length × width)2).
Histology and immunohistochemistry. Formalin-fixed lungs and zinc-fixed tumors were dehydrated 
and embedded in paraffin, serial 4-μ m-thick paraffin sections were stained with Haematoxylin-Eosin (H&E) or 
used for immunohistochemistry52. The number of lung macro metastases was macroscopically evaluated while 
micro metastases were microscopically studied at 20× magnification, as reported53. The number of tumor vessels 
per mm2 was evaluated at 200× magnification on zinc-fixed, rat monoclonal anti-CD31 stained sections (BD 
Pharmingen, San Diego, CA, USA), using amino-9-ethylcarbazole (AEC) as chromogen, Haematoxylin coun-
terstaining and positive and negative controls53. Double-blind measurements were performed in at least 10 ran-
domly selected fields for each specimen with the exclusion of necrotic areas, with an interobserver variability less 
than 5%.
Calcium imaging. B16 cells cultured on 35-mm dishes were incubated in culture medium containing 
3.5 μ mol/L FURA-2-AM (Invitrogen) for 1 h at 37 °C, and then rinsed with Hanks’ Balanced Salt Solution (HBSS, 
Sigma). Each dish was placed into a culture chamber at 37 °C on the stage of an inverted fluorescence microscope 
(TE2000E, Nikon Instruments, Fi, Italy), connected to a cooled CCD camera (512B Cascade, Roper Scientific, 
Ottobrunn, Germany). Samples were illuminated alternately at 340 and 380 nm using a random access mono-
chromator (Photon Technology International, New Jersey, USA) and emission was detected using a 510 nm emis-
sion filter. Images were acquired (1 ratio image per s) using Metafluor software (Universal Imaging Corporation, 
Downington PA, USA). Calibration was obtained at the end of each experiment by maximally increasing intra-
cellular Ca2+-dependent FURA-2AM fluorescence with 5 μ mol/L ionomycin (ionomycin calcium salt from 
Streptomyces conglobatus, Sigma) followed by recording minimal fluorescence in a Ca2+-free medium. [Ca2+]i 
was calculated according to the formulas previously described54.
Boyden chamber assay. The cell ability to migrate was evaluated by the Boyden chamber assay, which 
makes use of a chamber composed of two medium-filled compartments separated by a microporous membrane 
(8 μ m pore size, BD Bioscences). The lower well contained medium with 10% (vol/vol) serum. Cells were placed 
in the upper chamber in complete medium containing either Ned-19 or vehicle and allowed to migrate through 
the pores of the membrane into the lower compartment. After 24 h the membrane was fixed and Hoechst stained, 
and the number of cells that had migrated to the lower side of the membrane was evaluated in a Zeiss Axioscope 
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microscope (Zeiss, Mi, Italy). The number of migrating cells from three independent experiments were counted 
in 10 random view-fields per well and the values averaged.
Western Blot. Western blot was performed on B16 cells treated with Ned-19 for 24, 48 and 72 h. The intensity 
of bands was quantified by Image J software (NIH) from at least three independent experiments, normalized to 
β -actin content and compared with vehicle (DMSO)-treated controls (set as 1).
MTT test. To perform the methylthiazolyldiphenyl-tetrazolium (MTT, Sigma) test as a measurement of cell 
proliferation 5 mg/mL MTT was dissolved in PBS and filtered. B16 cells were cultured, detached using trypsin/
EDTA, then added onto 96-well plates at a concentration of 10 × 104 cells in 200 μ L DMEM per well and incubated in 
the specific experimental condition for 24 h. As a control for background absorption, cells were omitted in some of 
the wells. After incubation the medium was removed, 100 μ L serum-free medium (DMEM) containing 0.5 mg/mL 
MTT solution was added to each well and the plate was incubated in a humidified 5% (vol/vol) CO2 incubator at 
37 °C for 3 h to allow MTT to be metabolized. Then, 100 μ L DMSO (Sigma) were added to each well, pipetting up 
and down to dissolve crystals, and optical density was read at 570 nm.
Flow cytometric assessment of cell viability and growth. Cells were treated with Ned-19 or DMSO 
(vehicle). After 24, 48, 72 h, cells were harvested by trypsin/EDTA (Sigma), rinsed with PBS + 1% BSA (Sigma) 
and incubated with 1 μ g/mL propidium iodide (PI, Sigma). Cells were then analysed using a Beckam Coulter 
Epics XL flow cytometer (Beckman Coulter, Fullerton, CA) and data were analysed using FCS Express5 Flow 
Research Edition software (De Novo Software, Glendale, CA) to determine the number of dead vs alive cells for 
each experimental condition.
Cell cycle analysis. Propidium iodide (PI) staining: cells were detached with trypsin/EDTA, washed once 
with PBS, resuspended in 50% FCS in PBS and then fixed in 70% ethanol for 24 h. After washing three times with 
PBS, cells were incubated with 50 μ g/mL PI plus 0.1 U/L RNAse for 3 h at room temperature before FACS analysis 
by Coulter Epics XL flow cytometer (Beckman Coulter). Cells were gated using both area vs peak to eliminate 
doublets and forward vs side scatter to exclude debris. The percentage of cells in the different cycle phases and in 
subG1 (composed of dead cells and debris) was calculated using FCS Express5 Flow Research Edition software.
Annexin V-FITC staining. Cells were harvested by trypsin digestion, which was blocked by addition 
of serum followed by a wash in PBS, then treated with binding buffer containing PI and/or annexin V-FITC 
(Immunological Sciences, Rome, Italy) following the manufacturer’s instructions, prior to FACS analysis. 
Annexin V-FITC positive cells, either PI-negative or low PI positive, were considered as apoptotic. Since Ned-19 
has been reported to fluoresce31, a procedure was preliminarily devised to circumvent any possible interference 
with annexin V-FITC fluorescence. To this aim we set up a gate on cells unstained with annexin V-FITC and 
found that the median of fluorescence intensity (MFI) was 2.5 times higher in Ned-19- treated versus untreated 
cells. Therefore the FL1 positivity marker for Ned-19 treated samples was set to include the Ned-19 treated cells 
not stained with annexin V-FITC in the lower left quadrant.
Statistical analysis. Data are presented as the mean ± s.e.m. of results from at least three independent 
experiments. Student t test was used for statistical comparison between means where applicable. *P < 0.05; 
**P < 0.01; ***P < 0.0001.
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